Labour & childbirth
Oxytocin is a prescription medicine for labour and postpartum uterine atony or haemorrhage.
Explore the research →NEUROENDOCRINE & REPRODUCTIVE PHYSIOLOGY
Oxytocin
A naturally occurring hormone with established medical uses and wider research interest in bonding, social behaviour, emotion and brain health.
Labour & uterine toneMilk ejectionSocial cognition
Established medicine in obstetrics; mixed evidence for social usesIntravenous oxytocin has defined medical indications and supervision requirements. Intranasal social findings are context-dependent, and a large 24-week autism trial was negative.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
What makes oxytocin scientifically and clinically important?
Oxytocin is often called ‘the bonding hormone’, but its story is much broader. It has established roles in childbirth and breastfeeding, while research into trust, attraction, emotion and social connection has made it one of the most recognisable peptides linked with human behaviour.
Breastfeeding physiology
Naturally released oxytocin contracts myoepithelial cells during feeding.
Explore the research →Bonding & social connection
Acute intranasal studies explore emotion recognition, empathy, trust and reward.
Explore the research →Stress & emotional response
Research asks how oxytocin changes attention to social cues rather than simply making people calmer.
Explore the research →THE SCIENCE BIT
One hormone. Different effects in different tissues.
Oxytocin activates the oxytocin receptor. In uterine muscle and mammary tissue, this signalling supports contraction and the milk-ejection reflex.
The brain also uses oxytocin-related signalling, but social responses depend on context and the person. Calling it the 'bonding hormone' is shorthand, not a promise of trust, closeness or a predictable emotional effect.
See the studies & trials →- OXTR
- Oxytocin receptor
- Calcium signalling
- Supports muscle contraction
- Neural context
- Social effects are complex
How this connects to the research
Established obstetric pharmacology; intranasal behavioural evidence is mixed.
FROM MOLECULE TO TISSUE
Where Oxytocin connects with the body
These are the tissues and biological systems behind the interest in Oxytocin.
- Uterus
- Established contraction effects.
- Breast tissue
- Milk-ejection physiology.
- Brain
- Social and emotional research.
The research behind the interest
Labour & childbirth
Oxytocin has an established medical role in labour and after childbirth, where it is used in hospital to stimulate uterine contractions and control bleeding.
These are hospital indications using controlled infusion and maternal–fetal monitoring, not a wellness use.
Established clinical efficacyExplore the studies →Breastfeeding physiology
The body's own oxytocin also triggers the milk-ejection or ‘let-down’ reflex during breastfeeding.
This physiology is established, but breastfeeding difficulty has many causes and does not automatically indicate oxytocin deficiency.
Established physiologyExplore the studies →Bonding & social connection
The ‘bonding hormone’ label comes from research into trust, emotion and social behaviour, although the real effects are more complex and depend heavily on context.
A 2025 review found 24 IU was the most common research dose, but divergent results and contextual moderators limit generalisation.
Mixed human experimental evidenceExplore the studies →Stress & emotional response
Researchers are also interested in how oxytocin changes the way we notice and respond to emotional and social cues rather than simply making people feel calmer.
Effects can differ with sex, relationship, baseline traits, task and environment; one ‘bonding’ claim is too broad.
Context-dependent evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableCurrent UK obstetric product information ↗
Pregnant and postpartum patients under hospital supervision
Intravenous infusionTitrated by infusion pump for the indication
Indications include medically justified labour induction or stimulation and postpartum uterine atony or haemorrhage.
IV bolus administration is warned against because of acute hypotension, flushing and reflex tachycardia.
Intranasal oxytocin in children and adolescents with autism ↗
290 participants aged 3–17 years
IntranasalTarget 48 IU/day, usually 24 IU twice daily24 weeks
No improvement in the primary social-withdrawal outcome versus placebo.
Secondary social and cognitive outcomes generally did not differ.
Dose-response effects on social cognition ↗
Healthy adults across intranasal studies
Intranasal1–48 IU; 24 IU most common
Findings at 24 IU were not uniform; lower and higher doses also remained mixed.
Individual and contextual factors materially moderated response.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceExtensive
5/5 evidence depth
Extensive human exposure exists in obstetric medicine and intranasal research.
✓
Clinical efficacyExtensive
5/5 evidence depth
Efficacy is established for obstetric indications, not general bonding, anxiety or autism treatment.
◇
Safety evidenceExtensive
5/5 evidence depth
Licensed information defines major uterine, cardiovascular and water-balance risks.
⌁
Preclinical evidenceStrong
4/5 evidence depth
A large mechanistic literature covers oxytocin receptors, social salience and reproductive physiology.
HOW TO READ THESE SCORESStrong preclinical evidence · extensive human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
EVIDENCE LANDSCAPEOxytocinBiology → route → human outcome
Licensed infusion use in defined clinical settings
Acute signals vary by dose, person and context
Formulation, brain exposure and durable outcomes
Keep each claim attached to its route and outcome
An active biological pathway can justify a trial. It cannot make an untested formulation, indication or long-term schedule evidence-based.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Oxytocin
People explore intranasal oxytocin for connection, trust, social confidence, anxiety and intimacy. These goals overlap with laboratory outcomes, but oxytocin appears to alter social salience in context rather than deliver a predictable ‘bonding’ effect.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Feeling more connected with other people
Interest centres on warmth, closeness and easier interpersonal engagement. The bonding label is appealing, but social responses depend on the person, relationship and situation.
- What makes a report informative
- Specific interactions and the wider emotional context.
- What can muddy the picture
- Oxytocin is not a universal trust or connection switch.
Social confidence and less interpersonal tension
People may hope to feel more at ease in conversation or less guarded around others. A useful account distinguishes reduced anxiety from a meaningful change in social participation.
- What makes a report informative
- Comfort and participation in comparable situations.
- What can muddy the picture
- Familiarity, expectations and existing anxiety treatment can influence the experience.
Intimacy and clinical social-function research
Sexual and autism-related research attracts interest in more specialised outcomes. These are distinct uses, and experimental social-task effects cannot be treated as a general improvement in relationships.
- What makes a report informative
- The population, formulation and clinical endpoint studied.
- What can muddy the picture
- Intranasal research is not interchangeable with obstetric or injected use.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Connection and bonding
Users may expect warmer feelings or greater closeness.
Human findings & limits
Some acute studies report changes in trust or emotion recognition; many findings are mixed or null.
Laboratory & animal context
Receptor circuits support affiliative behaviour.
What this means: A genuine theme without a dependable person-independent effect.
Social confidence
The goal is often easier conversation or comfort in groups.
Human findings & limits
Outcomes vary with baseline anxiety, sex, diagnosis, familiarity and task.
Laboratory & animal context
Oxytocin can alter approach, threat and salience processing.
What this means: Context-sensitive evidence, not an established anxiolytic.
Autism-related social function
Oxytocin has been widely discussed for social communication.
Human findings & limits
A 290-participant, 24-week trial found no benefit over placebo.
Laboratory & animal context
Plausibility did not translate into the clinical outcome.
What this means: The strongest modern trial is an important negative result.
Intimacy and sexual wellbeing
Oxytocin is explored around closeness and sexual experience.
Human findings & limits
Small heterogeneous studies do not establish treatment for libido, arousal or relationships.
Laboratory & animal context
Reproductive and affiliative circuits provide interest.
What this means: A broad claim needing outcome-specific evidence.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
Oxytocin dosing is inseparable from indication and route: hospital infusion protocols must not be converted into intranasal wellness use.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
COMMUNITY DISCUSSION
Human research exposure · indication and formulation specificWhat people commonly discuss
STARTING APPROACHES
Single-dose social studies most often use 24 IU intranasally, but published doses span 1–48 IU without a dependable universal response.
DURATION / CYCLES
Repeated research ranges from brief experiments to 24 weeks; the large 24-week autism trial was negative.
MAINTENANCE DISCUSSION
No evidence-based maintenance schedule exists for bonding, wellbeing, relationship enhancement or social confidence.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Nasal and clinical formulation guide
Human research · indication-specificOxytocin is commonly reported in international units. Nasal social-cognition experiments do not establish a daily wellbeing regimen or an obstetric dose. Confirm the specific product and delivered IU; syringe markings and milligrams are not interchangeable with IU.
Form and route: Intranasal research products differ from obstetric injections
The planner keeps amounts and repeat patterns blank for this compound. Use its formulation guide to record an independently specified schedule.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with Oxytocin
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDOxytocin
→
OFTEN EXPLORED WITHOxytocin + labour care
Oxytocin infusion + Hospital monitoring
→
OFTEN EXPLORED WITHOxytocin + psychotherapy
Intranasal oxytocin + Structured psychological intervention
→
OFTEN EXPLORED WITHOxytocin + social setting
Acute oxytocin exposure + Partner, group or task context
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
＋
OFTEN EXPLORED WITH
Explore →＋Oxytocin + labour care
Oxytocin infusion + Hospital monitoringWHY IT IS EXPLOREDBenefit depends on titrated uterine response and maternal–fetal observation.
Established medical context; not transferable to self-use.OFTEN EXPLORED WITH
Explore →＋Oxytocin + psychotherapy
Intranasal oxytocin + Structured psychological interventionWHY IT IS EXPLOREDResearch asks whether social salience changes therapy engagement.
Results are condition-specific; no general synergy is established.OFTEN EXPLORED WITH
Explore →Oxytocin + social setting
Acute oxytocin exposure + Partner, group or task contextWHY IT IS EXPLOREDRelationship and task can modify response.
Context is a moderator, not a validated stack.Safety context
SAFETY & UNCERTAINTY
The word ‘natural’ hides route-specific medical risks
What the current evidence saysAdministered oxytocin can cause excessive uterine activity, fetal compromise, hypotension, tachycardia, QT-related problems and water intoxication or hyponatraemia. Obstetric use belongs in monitored care.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Why this matters
Intranasal formulations are not equivalent to prescription infusion products, and behavioural self-use has no approved long-term safety framework.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
8 sourcesSources used on this profile
Regulatory product informationCurrent UK obstetric product informationUK SmPC ↗Original human trialIntranasal oxytocin in children and adolescents with autismFree full paper ↗Original publicationIntranasal oxytocin in children and adolescents with autismJournal / DOI ↗Bibliographic recordIntranasal oxytocin in children and adolescents with autismPubMed ↗Trial registryIntranasal oxytocin in children and adolescents with autismClinicalTrials.gov ↗Original publicationDose-response effects on social cognitionJournal / DOI ↗Bibliographic recordDose-response effects on social cognitionPubMed ↗Professional sourceBehavioural / intranasal useClinicalTrials.gov ↗
CURRENT STATUS
How to interpret its position today
Prescription-only medicine for defined obstetric indications
UK product information covers labour and postpartum uterine atony or haemorrhage under hospital supervision.
UK SmPC ↗No general authorised social or wellbeing indication
Intranasal studies do not create approval for bonding, anxiety, autism or relationship enhancement.
ClinicalTrials.gov ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.